OCD Medication: SSRIs, ERP, and What to Expect

Selective serotonin reuptake inhibitors, or SSRIs, are a first-line medication option for OCD. They can be used alongside exposure and response prevention, and it may take 8 to 12 weeks to judge an adequate trial, so the decision to start, adjust, or stop one belongs with a qualified prescriber rather than a quick self-test.

Medication is not required for every person with OCD, and taking it is not a sign that therapy has failed. Some people begin with exposure and response prevention, some begin with medication, and some use both. The right route depends on how much symptoms are affecting daily life, what has helped before, other health considerations, access, and personal preference.

What medication is used for OCD?

SSRIs are generally the first medication class clinicians consider for OCD because research supports their benefit and they tend to be better tolerated than older alternatives. Several individual SSRIs are used, but approvals vary by country and age group. There is no single SSRI that is clearly best for everyone.

A prescriber may consider factors such as:

• Other physical and mental health conditions.
• Other prescribed medicines, supplements, alcohol, and drug use.
• Previous benefit or side effects from antidepressants.
• Pregnancy, breastfeeding, or plans to become pregnant.
• Age, family history, and any history of bipolar symptoms.
• Which side effects matter most to the person taking it.
• Local licensing, availability, and cost.

Clomipramine is another medicine with evidence for OCD. It is an older tricyclic antidepressant and can cause more troublesome or medically significant side effects than SSRIs, so guidelines commonly place it after one or more SSRI trials rather than using it first. Its use and monitoring require a clinician.

The word antidepressant can be confusing when the target is OCD. In this context, it names the drug class, not a conclusion that someone has depression. The same medicine can be used for more than one condition.

OCD medication and ERP are not competing treatments

The main evidence-based psychological treatment for OCD is cognitive behavioural therapy that includes exposure and response prevention. ERP helps a person approach relevant uncertainty, thoughts, sensations, objects, or situations while reducing the compulsions and avoidance that keep the cycle going.

Medication works through a different route. It may reduce overall OCD symptom severity, but it does not teach response prevention or make uncertainty disappear. ERP provides repeated practice in responding differently when the obsession-compulsion loop appears.

Guidelines treat both as legitimate options. NICE recommends a stepped approach for adults: lower-intensity ERP-based CBT may be considered for milder impairment, an SSRI or more intensive CBT with ERP may be offered when impairment is moderate, and combined SSRI plus CBT with ERP may be offered when impairment is severe. Those categories are clinical judgments, not a quiz to use on yourself.

Using both does not mean either treatment is incomplete. For some people, medication makes it more possible to take part in therapy. For others, ERP is workable without medication. Access, side effects, preference, symptom impact, and previous response all matter.

Why OCD medication can take longer than expected

An SSRI trial for OCD is usually measured in weeks, not days. The International OCD Foundation and current clinical guidance describe an adequate trial as roughly 8 to 12 weeks, with part of that time at a therapeutic dose. The NHS notes that benefit may take up to 12 weeks to appear.

That does not mean nothing can change before week eight, or that everyone must wait exactly 12 weeks. It means that an early week with little benefit does not necessarily answer whether the medicine can help. It also means dose changes should follow a prescriber’s plan. Doses used in OCD may differ from those used for depression, and the safest pace depends on the medicine, side effects, age, and health history.

Agreeing on a review date can make this waiting period clearer. Useful questions include what the prescriber considers an adequate trial, when they expect to review side effects, and what would justify an earlier call.

What improvement may look like

Medication response is not always a sudden feeling of being cured. Improvement may be gradual and incomplete. A clinician might look for changes such as:

• Obsessions taking up less time or feeling less sticky.
• A little more space between an urge and a compulsion.
• Rituals becoming shorter, less frequent, or easier to resist.
• Less avoidance of ordinary activities.
• Better ability to take part in ERP, work, study, sleep, or relationships.
• A meaningful change on a validated symptom measure, considered alongside daily functioning.

Intrusive thoughts can still occur when treatment is helping. The more useful question is often whether OCD is controlling less time and fewer choices, not whether every unwanted thought has disappeared.

Tracking can help a clinical conversation when it stays brief and purposeful. A weekly note about time, interference, compulsions, functioning, and side effects is often more informative than checking anxiety after every thought. If monitoring starts to become reassurance seeking, our guide to using an OCD app without turning it into a compulsion offers ways to set limits.

Side effects and early monitoring

SSRIs can cause side effects, especially after starting or changing a dose. The NHS lists possibilities including agitation, nausea or other digestive symptoms, dizziness, sleep changes, headaches, and sexual side effects. Not everyone has them, and their timing and severity vary.

Tell the prescriber what appears, how disruptive it is, and whether it is improving. Do not increase, skip, combine, or stop medicines in an attempt to solve a side effect without clinical advice. A pharmacist can also help explain how to take a prescribed medicine and check for interactions.

NICE recommends closer monitoring early in SSRI treatment and around dose changes, particularly for younger adults and anyone at increased risk of self-harm. Contact the prescriber promptly if agitation, restlessness, marked mood change, or distressing new symptoms appear. If suicidal thoughts emerge or you may be unable to stay safe, seek urgent local help. Find A Helpline lists crisis services by country.

Before starting, make sure the prescriber knows about every medicine and supplement being taken, relevant physical conditions, pregnancy or breastfeeding, and any past period of unusually elevated mood, reduced need for sleep, or risky behaviour. These details can change the safest plan.

If the first medication does not help enough

An incomplete response is a reason for review, not proof that nothing can help. Before calling a trial unsuccessful, a clinician may check whether the medicine was taken consistently, whether the duration and dose were adequate, whether side effects limited the plan, and whether another condition is affecting the picture.

Depending on that review, options can include:

• Continuing the current plan for the agreed trial period.
• Adding or strengthening CBT with ERP.
• Trying a different SSRI.
• Considering clomipramine with appropriate monitoring.
• Seeking specialist advice about an additional medicine after more standard options have been tried.
• Reassessing the diagnosis, co-occurring conditions, and barriers to treatment.

Some specialist augmentation strategies have research support, but they also carry important risks and are not do-it-yourself options. A list on the internet cannot account for a person’s medical history, interactions, or monitoring needs.

If access to appropriate therapy is the barrier, see how to find an OCD therapist and what to ask. A therapist’s use of the word CBT does not by itself confirm training in ERP.

How long do people stay on OCD medication?

There is no universal stop date. NICE recommends continuing an effective SSRI for at least 12 months because this can help maintain improvement and reduce relapse risk. After that, the decision to continue is reviewed in context, including symptom history, severity, previous relapses, remaining symptoms, side effects, and the person’s preference.

Stopping suddenly can cause withdrawal symptoms and may make it difficult to separate withdrawal from a return of OCD or another problem. When stopping is appropriate, the dose is normally reduced gradually with the prescriber. The pace may need to change if symptoms emerge.

Feeling better is therefore a reason to review the plan, not to end it alone. The same applies when medication feels ineffective or side effects are frustrating.

Questions to ask a prescriber

An appointment can be easier when the questions are written down. Consider asking:

1. What are we hoping will change? Define a few observable targets, such as time spent on rituals, avoidance, or ability to participate in ERP.
2. Why are you recommending this medicine for me? Ask how health history, other medicines, and preferences informed the choice.
3. What timeline counts as an adequate trial? Clarify when benefit and side effects will be reviewed.
4. What should I do if I miss a dose? The answer can differ by medicine.
5. Which side effects need a routine message, a prompt call, or urgent help? Know the contact route before it is needed.
6. Are there medicines, supplements, foods, alcohol, or drugs I should avoid? Include non-prescription products in the conversation.
7. How will this plan work with ERP? Ask whether the prescriber and therapist can coordinate when appropriate.
8. If this does not help enough, what would we review next? A next-step plan can reduce guesswork without promising a particular outcome.
9. If we eventually stop, how would tapering work? This is planning, not a commitment to stop now.

Bring a concise list of current medicines, major health conditions, previous trials, side effects, and the main ways OCD affects daily life. You do not need a perfect symptom diary or certainty about which treatment is right before asking for help.

A practical way to use Patterns alongside care

Patterns is a private journal and OCD companion, not a medication manager or a substitute for a prescriber. If you choose to use it during treatment, keep the role narrow: record an agreed weekly check-in, note meaningful side effects or functioning changes, and bring a short summary to an appointment.

Do not use the app to decide whether to change a dose, repeatedly check whether the medicine is working, or seek certainty after each intrusive thought. Medication decisions stay with a qualified professional. The record is there to support a conversation and show the broader pattern, then let you return to your day.

Sources

• International OCD Foundation: Medication for OCD
• International OCD Foundation: Exposure and Response Prevention
• NICE guideline CG31: Obsessive-compulsive disorder and body dysmorphic disorder
• NHS: Treatment for obsessive-compulsive disorder
• Fineberg, N. A., et al. (2025). Clinical advances in obsessive-compulsive disorder: a position statement and updated clinical practice guidelines. International Clinical Psychopharmacology.
• Shavitt, R. G., et al. (2023). Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Brazilian Journal of Psychiatry, 45(3), 288-299.